Dare Bioscience
DARE
25 hedge funds and large institutions have $1.87M invested in Dare Bioscience in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0.14% more ownership
Funds ownership: 6.9% → 7.04% (+0.14%)
2% less capital invested
Capital invested by funds: $1.9M → $1.87M (-$37.2K)
7% less funds holding
Funds holding: 27 → 25 (-2)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
US Bancorp
Minneapolis,
Minnesota
|
+$121K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$101K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$38.4K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$19.4K |
| 5 |
FFA
Farther Finance Advisors
San Francisco,
California
|
+$16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$90.5K |
| 2 |
VF
Virtu Financial
New York
|
-$37K |
| 3 |
Two Sigma Investments
New York
|
-$33.8K |
| 4 |
Jane Street
New York
|
-$20.4K |
| 5 |
HF
HRT Financial
New York
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Two Sigma Advisers
New York
| – | -$34.5K | -17,900 | Closed |
|
|
27
Jane Street
New York
| – | -$20.4K | -10,559 | Closed |
|
|
HF
28
HRT Financial
New York
| – | -$20K | -10,497 | Closed |
|
|
PA
29
Parallel Advisors
San Francisco,
California
| – | -$4.64K | -2,405 | Closed |
|
30
Bank of America
Charlotte,
North Carolina
| – | -$250 | -129 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$212 | -110 | Closed |
|
|
CPG
32
Cornerstone Planning Group
Fairfield,
New Jersey
| – | -$4 | -2 | Closed |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$101 | +59 | New |
|
DARE Hedge Fund Activity: Q1 2026 in Review
25 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q1 2026, worth a combined $1.87M — down 2% from $1.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of DARE and 7 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.
The largest buyer was US Bancorp, adding an estimated $121K. The largest seller was Susquehanna International Group, cutting an estimated $90.5K.
- 25 institutional investors held Dare Bioscience (DARE) as of Q1 2026, down from 27 in Q4 2025.
- Funds reported $1.87M of Dare Bioscience stock for Q1 2026, down 2% quarter-over-quarter.
- 7 funds opened new Dare Bioscience positions in Q1 2026 and 8 closed out, a net change of -1 holder.
- The largest Dare Bioscience buyer in Q1 2026 was US Bancorp, an estimated $121K added.
- The largest Dare Bioscience seller in Q1 2026 was Susquehanna International Group, an estimated $90.5K sold.
Based on aggregated 13F filings for Q1 2026.